- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 429-443 of
901 results
2465 Exhibit: EX2465 US Food Drug Administration, DrugsFDA, Steglatro
Document
IPR2023-00724, No. 2465 Exhibit - EX2465 US Food Drug Administration, DrugsFDA, Steglatro (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2075 Exhibit: EX2075 Madsbad, S et al, “Improved Glycemic Control With No Weigh...
Document
IPR2023-00724, No. 2075 Exhibit - EX2075 Madsbad, S et al, “Improved Glycemic Control With No Weight Increase in Patients With Type 2 Diabetes After Once Daily Treatment With the Long Ac...
|
|
Cite Document
2059 Exhibit: EX2059 Declaration of Vanessa Costain
Document
IPR2023-00724, No. 2059 Exhibit - EX2059 Declaration of Vanessa Costain (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2510 Exhibit: EX2510 Novo Nordisk, Financial report for the period 1 January 2022...
Document
IPR2023-00724, No. 2510 Exhibit - EX2510 Novo Nordisk, Financial report for the period 1 January 2022 to 31 March 2022 Apr 29, 2022 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2058 Exhibit: EX2058 Declaration of Sayem Osman
Document
IPR2023-00724, No. 2058 Exhibit - EX2058 Declaration of Sayem Osman (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2367 Exhibit: EX2367 Sirtori, CR and Pasik, C, Re evaluation of a biguanide, metfo...
Document
IPR2023-00724, No. 2367 Exhibit - EX2367 Sirtori, CR and Pasik, C, Re evaluation of a biguanide, metformin mechanism of action and tolerability, Pharmacol Res 1994 Oct Nov 303187 228 (P....
|
|
Cite Document
2422 Exhibit: EX2422 Jentadueto® Prescribing Information rev Aug 2017
Document
IPR2023-00724, No. 2422 Exhibit - EX2422 Jentadueto® Prescribing Information rev Aug 2017 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2385 Exhibit: EX2385 Wilding, JPH, The importance of weight management in type ...
Document
IPR2023-00724, No. 2385 Exhibit - EX2385 Wilding, JPH, The importance of weight management in type 2 diabetes mellitus, Int J Clin Pract, 2014 Jun 686682 691 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2417 Exhibit: EX2417 AstraZeneca, “AstraZeneca and Bristol Myers Squibb compl...
Document
IPR2023-00724, No. 2417 Exhibit - EX2417 AstraZeneca, “AstraZeneca and Bristol Myers Squibb complete expansion of diabetes alliance through Bristol Myers Squibb’s acquisition of Amylin P...
|
|
Cite Document
2506 Exhibit: EX2506 Novo Nordisk, Financial report for the period 1 January 2021...
Document
IPR2023-00724, No. 2506 Exhibit - EX2506 Novo Nordisk, Financial report for the period 1 January 2021 to 31 March 2021 May 5, 2021 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2113 Exhibit: EX2113 Victoza® FDA Approval Letter Jan 25, 2010
Document
IPR2023-00724, No. 2113 Exhibit - EX2113 Victoza® FDA Approval Letter Jan 25, 2010 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2440 Exhibit: EX2440 US Food Drug Administration, DrugsFDA, Jardiance®
Document
IPR2023-00724, No. 2440 Exhibit - EX2440 US Food Drug Administration, DrugsFDA, Jardiance® (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2425 Exhibit: EX2425 Jentadueto® XR Prescribing Information rev Dec 2016
Document
IPR2023-00724, No. 2425 Exhibit - EX2425 Jentadueto® XR Prescribing Information rev Dec 2016 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2071 Exhibit: EX2071 Claim Construction Order, In re Ozempic Semaglutide Paten...
Document
IPR2023-00724, No. 2071 Exhibit - EX2071 Claim Construction Order, In re Ozempic Semaglutide Patent Litigation, MDL No 22 MD 3038, Dkt No 148 D Del July 25, 2023 (P.T.A.B. Jan. 17, 2024...
|
|
Cite Document
2084 Exhibit: EX2084 R Pratley et al, “Semaglutide versus dulaglutide once weekly...
Document
IPR2023-00724, No. 2084 Exhibit - EX2084 R Pratley et al, “Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes SUSTAIN 7 a randomized, open label, phase 3b trial,” La...
|
|
Cite Document
